AKTS

Aktis Oncology, Inc.

Price Chart

Latest Quote

$18.87

-1.02 (-5.13%)

Current Price

Previous Close	$19.89
Open	$19.87
Day High	$20.23
Day Low	$18.75
Volume	138,619

Fetched: 2026-06-06T11:32:29

Stock Information

Shares Outstanding	53.40M
Total Debt	$11.58M
Cash Equivalents	$538.48M
Revenue	$8.28M
Net Income	$-67.07M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.04B
EPS (TTM)	$-1.21
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$516.18M
Sales	$8.28M
Income	$-67.07M
Book/sh	$9.16
Cash/sh	$10.08
Employees	79

Financial Ratios

Quick Ratio	19.37
Current Ratio	19.49
Debt/Eq	2.29

Returns & Margins

Operating Margin

-703.63%

Ownership

Insider Ownership	14.14%
Institutional Ownership	74.22%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-9.48
P/S	126.02
P/B	2.06

Analyst Data

Recommendation	strong_buy
Target Price	$32.65

Technical Indicators

SMA20	$19.52
SMA50	$18.97
RSI	46.26
ATR	1.3207

Shares Float	28.15M
Short Float	15.97%
Short Ratio	12.36
Rel Volume	0.90

Performance History

Week	-9.02%
Month	-5.79%
Quarter	+0.32%
YTD	-15.76%
10 Years	-15.76%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$18.87	138,600
2026-06-04	$19.89	151,700
2026-06-03	$19.37	269,400
2026-06-02	$20.26	310,100
2026-06-01	$19.48	98,700
2026-05-29	$20.74	142,000
2026-05-28	$20.43	99,600
2026-05-27	$19.92	157,000
2026-05-26	$20.58	166,100
2026-05-22	$20.34	129,700
2026-05-21	$19.12	147,300
2026-05-20	$19.03	124,200
2026-05-19	$18.50	194,400
2026-05-18	$18.61	155,800
2026-05-15	$19.55	142,800
2026-05-14	$19.50	114,600
2026-05-13	$19.53	129,500
2026-05-12	$19.73	149,700
2026-05-11	$18.27	134,300
2026-05-08	$18.60	117,600
2026-05-07	$18.84	171,500
2026-05-06	$20.03	163,100

About Aktis Oncology, Inc.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

📰 Latest News

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound

Simply Wall St. • 2026-05-25T19:05:38Z

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

Motley Fool • 2026-05-13T20:30:31Z

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

MarketBeat • 2026-05-05T14:14:50Z

Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump

Simply Wall St. • 2026-04-26T13:04:32Z

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know

Zacks • 2026-04-17T13:55:02Z

H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33

Insider Monkey • 2026-04-12T21:18:15Z

Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs

MarketBeat • 2026-03-10T03:05:31Z

Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference

MarketBeat • 2026-03-04T01:02:54Z

Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound

Simply Wall St. • 2026-02-25T14:13:51Z

Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut

Reuters • 2026-02-05T18:21:50Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$6,497,000	$1,487,000	$0	$0
Operating Revenue	$6,497,000	$1,487,000	$0	$0
Expenses
Total Expenses	$81,181,000	$53,537,000	$34,794,000	$19,764,000
Other Income Expense	$-56,000	$-33,000	$776,000	$188,000
Other Non Operating Income Expenses	$-56,000	$-25,000	$-24,000	$-12,000
Net Non Operating Interest Income Expense	$11,009,000	$8,103,000	$5,377,000	$1,647,000
Operating Expense	$81,181,000	$53,537,000	$34,794,000	$19,764,000
General And Administrative Expense	$12,598,000	$11,307,000	$7,679,000	$5,106,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Net Interest Income	$11,009,000	$8,103,000	$5,377,000	$1,647,000
Interest Income	$11,009,000	$8,103,000	$5,377,000	$1,647,000
Normalized Income	$-63,731,000	$-43,972,000	$-29,441,000	$-18,129,000
Net Income From Continuing And Discontinued Operation	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Total Operating Income As Reported	$-74,684,000	$-52,050,000	$-34,794,000	$-19,764,000
Net Income Common Stockholders	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Net Income	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Net Income Including Noncontrolling Interests	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Net Income Continuous Operations	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Pretax Income	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Interest Income Non Operating	$11,009,000	$8,103,000	$5,377,000	$1,647,000
Operating Income	$-74,684,000	$-52,050,000	$-34,794,000	$-19,764,000
Depreciation Amortization Depletion Income Statement	$1,132,000	$1,276,000	$1,196,000	$356,000
Depreciation And Amortization In Income Statement	$1,132,000	$1,276,000	$1,196,000	$356,000
Depreciation Income Statement	$1,132,000	$1,276,000	$1,196,000	$356,000
Per Share
Diluted EPS	$-1.21	$-1.26	$-0.82	$-0.51
Basic EPS	$-1.21	$-1.26	$-0.82	$-0.51
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-72,355,000	$-50,467,000	$-34,398,000	$-19,519,000
Reconciled Depreciation	$2,329,000	$1,575,000	$1,120,000	$445,000
EBITDA (Bullshit earnings)	$-72,355,000	$-50,475,000	$-33,598,000	$-19,319,000
EBIT	$-74,684,000	$-52,050,000	$-34,794,000	$-19,764,000
Diluted Average Shares	$52,522,279	$34,864,855	$34,864,855	$34,864,855
Basic Average Shares	$52,522,279	$34,864,855	$34,864,855	$34,864,855
Diluted NI Availto Com Stockholders	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Research And Development	$67,451,000	$40,954,000	$25,919,000	$14,302,000
Selling General And Administration	$12,598,000	$11,307,000	$7,679,000	$5,106,000
Other Gand A	$4,922,000	$5,164,000	$2,917,000	$2,177,000
Salaries And Wages	$7,676,000	$6,143,000	$4,762,000	$2,929,000
Total Unusual Items	-	$-8,000	$800,000	$200,000
Total Unusual Items Excluding Goodwill	-	$-8,000	$800,000	$200,000
Gain On Sale Of Security	-	$-8,000	$800,000	$200,000

Fetched: 2026-05-30

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Total Assets	$264,885,000	$326,181,000	$122,355,000	$138,322,000
Total Non Current Assets	$34,575,000	$25,328,000	$22,151,000	$5,841,000
Other Non Current Assets	$7,329,000	$4,457,000	$1,227,000	$976,000
Current Assets	$230,310,000	$300,853,000	$100,204,000	$132,481,000
Other Current Assets	$3,523,000	$3,685,000	$2,342,000	$3,884,000
Cash Cash Equivalents And Short Term Investments	$226,787,000	$297,168,000	$97,862,000	$128,597,000
Cash And Cash Equivalents	$37,784,000	$37,159,000	$29,513,000	$128,597,000
Debt
Total Debt	$11,548,000	$12,010,000	$13,402,000	$1,775,000
Long Term Debt And Capital Lease Obligation	$10,233,000	$10,714,000	$11,874,000	$921,000
Current Debt And Capital Lease Obligation	$1,315,000	$1,296,000	$1,528,000	$854,000
Liabilities
Total Liabilities Net Minority Interest	$411,034,000	$413,984,000	$168,661,000	$157,552,000
Total Non Current Liabilities Net Minority Interest	$379,798,000	$395,162,000	$162,424,000	$152,277,000
Non Current Deferred Liabilities	$36,156,000	$51,039,000	$0	-
Current Liabilities	$31,236,000	$18,822,000	$6,237,000	$5,275,000
Current Deferred Liabilities	$18,662,000	$9,277,000	$0	-
Payables And Accrued Expenses	$6,695,000	$5,165,000	$2,676,000	$3,227,000
Payables	$1,737,000	$1,918,000	$957,000	$490,000
Accounts Payable	$1,737,000	$1,918,000	$957,000	$490,000
Derivative Product Liabilities	-	$0	$500,000	$1,300,000
Other Non Current Liabilities	-	-	-	$6,000
Equity
Common Stock Equity	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Total Equity Gross Minority Interest	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Stockholders Equity	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Gains Losses Not Affecting Retained Earnings	$42,000	$124,000	$82,000	$0
Other Equity Adjustments	$42,000	$124,000	$82,000	-
Retained Earnings	$-156,564,000	$-92,833,000	$-48,853,000	$-20,212,000
Preferred Securities Outside Stock Equity	$333,409,000	$333,409,000	$150,050,000	$150,050,000
Other
Ordinary Shares Number	$52,522,279	$52,522,279	$52,522,279	$52,522,279
Share Issued	$52,522,279	$52,522,279	$52,522,279	$52,522,279
Tangible Book Value	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Invested Capital	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Working Capital	$199,074,000	$282,031,000	$93,967,000	$127,206,000
Capital Lease Obligations	$11,548,000	$12,010,000	$13,402,000	$1,775,000
Total Capitalization	$-146,149,000	$-87,803,000	$-46,306,000	$-19,230,000
Additional Paid In Capital	$10,373,000	$4,906,000	$2,465,000	$982,000
Capital Stock	$0	$0	$0	$0
Common Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$36,156,000	$51,039,000	$0	-
Long Term Capital Lease Obligation	$10,233,000	$10,714,000	$11,874,000	$921,000
Current Deferred Revenue	$18,662,000	$9,277,000	$0	-
Current Capital Lease Obligation	$1,315,000	$1,296,000	$1,528,000	$854,000
Pensionand Other Post Retirement Benefit Plans Current	$4,564,000	$3,084,000	$2,033,000	$1,194,000
Current Accrued Expenses	$4,958,000	$3,247,000	$1,719,000	$2,737,000
Net PPE	$27,246,000	$20,871,000	$20,924,000	$4,865,000
Accumulated Depreciation	$-5,545,000	$-3,229,000	$-1,653,000	$-533,000
Gross PPE	$32,791,000	$24,100,000	$22,577,000	$5,398,000
Leases	$167,000	$167,000	$167,000	$167,000
Construction In Progress	$7,007,000	$1,332,000	$395,000	$557,000
Other Properties	$24,800,000	$21,847,000	$21,289,000	$4,403,000
Machinery Furniture Equipment	$817,000	$754,000	$726,000	$271,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$189,003,000	$260,009,000	$68,349,000	$0

Fetched: 2026-05-30

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-73,711,000	$11,900,000	$-33,768,000	$-20,432,000
Operating Activities
Operating Cash Flow	$-64,127,000	$14,762,000	$-30,004,000	$-18,125,000
Cash Flow From Continuing Operating Activities	$-64,127,000	$14,762,000	$-30,004,000	$-18,125,000
Operating Gains Losses	-	$8,000	$-800,000	$-200,000
Investing Activities
Capital Expenditure	$-9,584,000	$-2,862,000	$-3,764,000	$-2,307,000
Investing Cash Flow	$65,964,000	$-190,400,000	$-68,828,000	$-2,307,000
Cash Flow From Continuing Investing Activities	$65,964,000	$-190,400,000	$-68,828,000	$-2,307,000
Financing Activities
Issuance Of Capital Stock	$0	$185,000,000	$0	$120,135,000
Financing Cash Flow	$-1,212,000	$183,284,000	$0	$119,984,000
Cash Flow From Continuing Financing Activities	$-1,212,000	$183,284,000	$0	$119,984,000
Net Other Financing Charges	$-1,548,000	$-1,895,000	-	$-151,000
Net Preferred Stock Issuance	$0	$185,000,000	$0	$120,135,000
Preferred Stock Issuance	$0	$185,000,000	$0	$120,135,000
Other
End Cash Position	$38,933,000	$38,308,000	$30,662,000	$129,494,000
Beginning Cash Position	$38,308,000	$30,662,000	$129,494,000	$29,942,000
Changes In Cash	$625,000	$7,646,000	$-98,832,000	$99,552,000
Proceeds From Stock Option Exercised	$336,000	$179,000	$0	-
Net Investment Purchase And Sale	$75,548,000	$-187,538,000	$-65,121,000	$0
Sale Of Investment	$269,416,000	$100,858,000	$80,685,000	$0
Purchase Of Investment	$-193,868,000	$-288,396,000	$-145,806,000	$0
Net PPE Purchase And Sale	$-9,584,000	$-2,862,000	$-3,707,000	$-2,307,000
Purchase Of PPE	$-9,584,000	$-2,862,000	$-3,764,000	$-2,307,000
Change In Working Capital	$-3,232,000	$58,980,000	$-15,000	$-1,139,000
Change In Other Working Capital	$-5,498,000	$58,513,000	-	-
Change In Other Current Liabilities	$-1,401,000	$-1,522,000	$-2,284,000	$-566,000
Change In Other Current Assets	$1,349,000	$820,000	$1,829,000	$507,000
Change In Payables And Accrued Expense	$2,156,000	$2,512,000	$432,000	$2,536,000
Change In Accrued Expense	$2,200,000	$2,152,000	$-227,000	$2,537,000
Change In Payable	$-44,000	$360,000	$659,000	$-1,000
Change In Account Payable	$-44,000	$360,000	$659,000	$-1,000
Change In Prepaid Assets	$-872,000	$-482,000	$265,000	$-3,616,000
Change In Receivables	$1,034,000	$-861,000	$-257,000	$0
Stock Based Compensation	$5,131,000	$2,260,000	$1,478,000	$698,000
Amortization Of Securities	$-4,624,000	$-4,081,000	$-3,146,000	$0
Depreciation Amortization Depletion	$2,329,000	$1,575,000	$1,120,000	$445,000
Depreciation And Amortization	$2,329,000	$1,575,000	$1,120,000	$445,000
Net Income From Continuing Operations	$-63,731,000	$-43,980,000	$-28,641,000	$-17,929,000
Sale Of PPE	-	$0	$57,000	$0
Gain Loss On Investment Securities	-	$8,000	$-800,000	$-200,000

Fetched: 2026-05-30